Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Absolutely no deramping from my side. Significant holder here for the last 4 years who is in no way affected by timescales
“the only price that matters is the last one”
Yes I don’t disagree. Many internal and external factors to be taken in consideration into not just this trial, but all clinical trials. Hence why the calculated average should be very much taken with a pinch of salt
For obvious reasons, the C6 57 days is an estimation and based off C5 end date (all we officially have).
As you can see, the C6 figures were not added to the calculated average because:
A) the company has not provided an official start
B) C6 is still underway
My notes for cohort lengths say:
C1: 176 days (80mg)
C2: 146 days (120mg)
C3: 64 days (160mg)
C4: 109 days (200mg)
C5: 78 days (250mg)
C6: 57 days as of 16/08/2023 (310mg)
Average: 114 days (from 5 cohorts)
About Outsourcing-Pharma
William Reed’s Outsourcing-Pharma has been the leading online news source for the pharma industry for more than 16 years, leveraging our digital-first position to bring powerful insights and robust information to help your business succeed.
Outsourcing-Pharma offers 360-degree coverage of the pharma landscape, providing industry professionals news focused on clinical trials, commercial development and manufacture of small molecule drugs.
About the publisher: William Reed
William Reed is a specialist B2B media, business intelligence and events group.
Their diverse portfolio of category-leading brands serves a global audience of almost 5M monthly users, supported by sector-specific insights & research, up-to-the-minute digital media and cutting-edge customer solutions.
Big Pharma
Order of events since 3996 candidate selection:
17/01/23
Avacta gains 14% after completing fourth dose escalation in cancer drug trial
17/01/23
Avacta Group plc announces successful completion of fourth dose escalation in Phase 1 clinical study of AVA6000
08/11/22
Avacta Group says its open offering is heavily oversubscribed
2022
AVACTA GROUP PLC: RIGHTS ISSUE: 3 new shares @ 0.95 GBP for 365 existing shares
2022
Avacta Group raises $67 million through equity placement and convertible bond issuance.
2022
Avacta Plans $70 Million Equity Placement and Convertible Bond Issuance to Fund Launch of Diagnostic Products Purchase
2022
Avacta will acquire Launch Diagnostics for up to $42 million.
2022
Avacta Group Plc announces results for the six months ended June 30, 2022
2022
Avacta's Chemotherapy Drug Receives Orphan Drug Designation from US FDA
2022
Avacta advances early-stage study of new form of chemotherapy drug to fourth dose cohort
2022
Avacta Group plc Announces Phase I Study of AVA6000 Advances to Cohort Four
2022
LG Chem license renewal triggers payment to Avacta Group Plc
2022
Avacta Group Plc Announces Second Dose Escalation in Phase I Clinical Study of AVA6000 Pro-Doxorubicin
2022
Avacta JV extends drug manufacturing agreement with GenScript
2022
Avacta is increasing its stake in the AffyXell Therapeutics joint venture after securing a milestone equity payment.
2022
Avacta JV Enters into Partnerships to Develop In Vivo Models of Immune Diseases for Drug Candidates; shares up 9%.
2022
Avacta Group Plc, 2021 Earnings Call, Apr 06, 2022
2022
Avacta Group Plc announces its results for the full year ending December 31, 2021
2022
Avacta Appoints Dr. Christina Coughlin as Non-Executive Director
2022
Avacta sells its veterinary division to Swedish company Vimian
2022
Vimian Group AB (publ) (OM:VIMIAN) has acquired Sensitest from Avacta Group Plc (AIM:AVCT) for £2.3 million.
2022
Avacta Announces Dose Escalation in Phase I Clinical Study of AVA6000 Pro-Doxorubicin
2022
Avacta advances early-stage chemotherapy trial to next dose after positive safety data
2022
Avacta's pre|CISION platform drug selected for preclinical development
2022
Avacta Group plc selects second pro-drug candidate for development of Pre|Cision
What makes a great investment? Top notch technology, a wide economic moat, excellent management and an attractive valuation. IMO, life sciences firm Avacta has all four.
Today it said that the results from its Phase 1 study wrt its pro-doxorubicin (AVA6000) treatment for cancerous tumours HAD MET ITS PRIMARY GOAL.
Indeed reading between the lines, I suspect the data may have even surpassed the scientists’ own expectations. Not only confirming AVA6000's safety profile, which continued to be well tolerated by the 19 trial patients. Including those in Cohort 4 at the highest dosing levels - equivalent to >2x the normal dose of doxorubicin.
But also, after analysing a number of tumour biopsies across different cohorts. The results showed that AVA6000 had successfully released its chemo-warhead (ie doxorubicin) around the tumour. Importantly too, at therapeutic levels which were much higher than those detected in the bloodstream.
Frankly fabulous news, since doxorubicin is already well known to be an effective treatment for cancer.
Consequently, the Safety Data Monitoring Committee has recommended continuation to higher dose cohorts with the aim of identifying a maximum tolerated dose to be used within the Phase 1b & future studies. This work should be completed by the end of Jun’23.
CEO Alastair Smith commenting: “We’re delighted with the very positive data emerging from the dose escalation study of our lead pre|CISION tumour targeted therapy AVA6000. The very significant reduction in toxicities, plus the observed release of doxorubicin in the tumour tissue at significant levels, show that the pre|CISION platform has the potential to significantly improve the safety & tolerability of chemotherapies, and other drugs, by targeting their release to the tumour.”
So what does this mean wrt valuation?
Well, I suspect many investors had previously under-estimated AVA6000’s chances of success. In fact before today’s RNS, even analysts at Trinity Delta had used standard industry failure rates of 90% in their risk adjusted models.
To me, a more tailored solution should be adopted. Especially given some of the most common problems associated with drug discovery don’t seem to apply as much here.
Moreover, the TAM for FAPa-activated drugs like AVA6000, the wider pre|CISION platform & chemotherapies in general is predicted to be worth $56bn by 2024.
Meaning if AVA6000 ultimately proves to be successful, then this could provide a major lift to the stock.
How much is anybody’s guess - albeit assuming a re-appraised 25%-50% success rate - I estimate Trinity Delta’s valuation could hypothetically be upgraded from 219p to between 330p-580p per fully diluted share.
Better still, AVA6000 is not the only value driver either.
Avacta also has a host of other ‘shots on goal’, not least its proprietary Affimer therapeutics & diagnostics platform, promising 3rd party licensing deals and recent £24m acquisition of Launch Diagnostics
@MylesMcNulty
Having held #AVCT for over 3 years now, a maximum of 28 sessions for an update on #AVA6000 (until SD on 23 Feb) is no wait at all.
And I agree with you: no update yet means it's likely (IMO) that a commercial deal (of what nature? ?????) is being finalized
Surely the key update in “early Jan” will provide the information required to entice city analysts and fund managers to attend/selected key opinion leaders in the field of oncology to speak at the Science Day event on 23rd February 2023…
A quick update on the CanSeek agreement between Avacta and Point:
The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.
Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT
The demise of Cineworld would be a grave day for the entire entertainment business. Exhibition is vital for Hollywood as it does a tremendous job being the most immersive art medium and the most collective one. If Regal were to go it could be the start of a domino effect which will see more exhibitioners like AMC, Cinemark and Cineplex heading the same way. Big budget movies would reluctantly be signed off as movies are scaled down for streaming and television. Talent including writers, directors would have to scale down their story telling, which would hurt the entire movie ecosystem. Hundreds of thousands of jobs would be effected upstream and down. Footfall to shopping centres and leisure centres. For what? Creditors who are too short sighted to see a recovery is coming and a black swan event that exhibition has had to navigate?
Save Cineworld, save cinema culture
1. The past twelve months have seen significant progress in Avacta’s Therapeutics Division with the approval of a Clinical Trial Application in the UK and the dosing of the first patient in the Phase I, first-in-human, open label, dose-escalation and expansion study of its lead pre|CISIONTM FAPa-activated drug, AVA6000, in patients with locally advanced or metastatic selected solid tumours. This marks the transformation of Avacta into a clinical stage oncology drug company which is a major value inflection point
2. The dose escalation phase is anticipated to complete in the middle of 2022 with minimal delay and should be followed by initiation of the dose expansion phase in 2022 which would be expected to complete by the end of 2023.
3. With its strong balance sheet, the Group expects to deliver major value inflection points from its well-funded therapeutic programmes over the next twelve months and deliver near- to medium-term revenues from its diagnostic business, driving long-term shareholder value.
4. The Group also anticipates further commercial partnerships and licensing arrangements that will allow its technology platforms to be further developed leading to long term royalty based revenue in both the therapeutics and other markets.
Agreed, some bullish, forward looking comments from both FMcL and Neil Bell:
“Bench to bedside”
“Poised to take Avacta to the next stage in its evolution as a clinical stage bio pharmaceutical company”
“Transformational milestone”
“Take the business forward”
Onwards Avacta!
But is it as big as AVACTA’s?! ;)
Sierra do have a pipeline ;)
Yes this is fantastic news and shows you what can happen, out of the blue, in little time. In-fact, a “little”, AIM listed drug discovery and development company, called Sareum, headquartered in Cambridge UK, that produces targeted small molecule therapeutics (focusing on cancer treatment) out-licensed one of their Stage 1/2 cancer treatment molecules (SRA737) to Sierra a few years ago. This now sits under the umbrella of one of the world’s largest Pharma giants. Just goes to show how much exposure to large pharmas these “little” AIM listed companies can have.
This is quite simply incredible news. Conveniently, one of the largest Pharma giants in the world has now also acquired a license to one of the few CHK1 inhibitors there are left...
SimonPhoenix - "AVA6K dosed at SIX times higher than Doxorubicin and yielding SIGNIFICANTLY better results. Oh and by the way, Doxorubicin is only an approved, market leading anti-cancer treatment.
Retireby40 - "The above is good but would it not be better to see 6K having Better results using a comparable dose rather than 6 times?"
Doxorubicin is a potent anticancer agent with cytotoxic effects that limit its clinical usage. Although proven to assist in the shrinkage of tumors, it comes with a raft of adverse effects. These include irreversible heart muscle damage and may even increase the risk of developing leukemia (cancer of the white blood cells), especially when administered in high doses.
Doxorubicin dosage is generally calculated on the basis of body weight. With results showing that administration of doxorubicin as a single dose every three weeks greatly reduces the distressing toxic effect. However, studies have shown that dividing the dose over three successive days (0.4-0.8mg/kg each day) gives greater effectiveness, though at the cost of higher toxicity.
As stated in the poster: 'Dox concentration was only detected in FAP enzyme.' Ie. AVA6000 releases active drug only in the tumor. If AV6000 can deliver Doxorubicin directly to the tumor in higher doses, with less of a gap required between these doses, then AVA6000 will limit the systemic exposure and improve the overall safety and therapeutic potential of this powerful anti-cancer treatment.
YES! And the market size of that leading anti-cancer treatment is expected to grow to $1.38 BILLION in 2 years time.
All this for the basement price of just above £1 a share.
Definition of opportunity
1 : a favorable juncture of circumstances
2 : a good chance for advancement or progress